实体瘤免疫治疗疗效评价标准

doi:10.3760/cma.j.issn.1673-422X.2016.11.012

摘要/Abstract

摘要： 免疫治疗已经成为实体瘤除手术、放疗、化疗、靶向治疗之外的重要治疗手段。然而免疫治疗的作用机制不同于既往的治疗手段，它是通过激活机体的免疫效应而杀伤肿瘤细胞，达到肿瘤负荷的下降及生存期延长的目的。所以传统的世界卫生组织（WHO）疗效评价标准和实体瘤疗效评价标准（RECIST）也就很难对肿瘤免疫治疗的临床疗效进行准确解读，新的免疫疗效评价标准则涵盖了免疫疗效的各种表现形式，正逐渐应用于临床。

关键词: 肿瘤, 免疫疗法, 疗效评价

Abstract: Immunotherapy has become an important therapy for solid tumors, which is in addition to surgery, radiotherapy, chemotherapy and targeted therapy. However immune treatment mechanism is different from those previous treatment. The effect of immunotherapies is on the immune system and not directly on the tumor. The kinetics of immunotherapy is characterized by a cellular immune response followed by potential changes in tumor burden and survival period. They are not captured by the traditional World Health Organization (WHO) or the Response Evaluation Criteria in Solid Tumors (RECIST). New immunerelated response criteria are defined which more comprehensively capture all response patters and gradually applied in clinical practice.

Key words: Neoplasms, Immunotherapy, Response evaluation

张萍，艾斌. 实体瘤免疫治疗疗效评价标准[J]. 国际肿瘤学杂志, 2016, 43(11): 848-851.

Zhang Ping, Ai Bin. Efficacy evaluation criteria for immunotherapy in solid tumors[J]. Journal of International Oncology, 2016, 43(11): 848-851.

参考文献

［1］ Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment［J］. Cancer Res, 2012, 72(13): 3125-3130. DOI: 10.1158/0008-5472.CAN-11-4094. ［2］ Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an antiCTLA4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases［J］. Cancer Immunol Immunother, 2009, 58(8): 12971306. DOI: 10.1007/s002620080642y. ［3］ Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an antiPD1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257265. DOI: 10.1016/S14702045(15)700549. ［4］ Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients［J］. Proc Natl Acad Sci USA, 2008, 105(8): 3005-3010. DOI: 10.1073/pnas.0712237105. ［5］ Cohen JV, Alomari AK, Vortmeyer AO, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment［J］. Cancer Immunol Res, 2016, 4(3): 179-182. DOI: 10.1158/2326-6066.CIR-15-0160. ［6］ Hodi FS, Ribas A, Daud A, et al. Evaluation of immunerelated response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the antiPD-1 monoclonal antibody MK3475［J］. J Clin Oncol, 2014, 32(5s): abstr 3006. ［7］ F.Stephen Hodi, Mario Sznol, Harriet M. Kluger, et al. Longterm survival of ipilimumabnaive patients (pts) with advanced melanoma (MEL) treated with nivolumab (antiPD-1, BMS936558, ONO4538) in a phase Ⅰ trial［J］. J Clin Oncol, 2014, 32(5s): abstr 9002. ［8］ Wolchok JD, Hoos A, O′day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria［J］. Clin Cancer Res, 2009, 15(23): 7412-7420. DOI: 10.1158/1078-0432.CCR-09-1624. ［9］ Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics［J］. J Immunother, 2007, 30(1): 1-15. DOI: 10.1097/01.cji.0000211341.88835.ae. ［10］ Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy?［J］. Clin Cancer Res, 2009, 15(23): 7116-7118. DOI: 10.1158/1078-0432.CCR-09-2376. ［11］ Chiou VL, Burotto M. Pseudoprogression and immunerelated response in solid tumors［J］.J Clin oncol, 2015, 33(31): 35413543. DOI:10.1200/JCO.2015.61.6870. ［12］ O′day SJ, Maio M, ChiarionSileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter singlearm phase Ⅱ study［J］. Ann Oncol, 2010, 21(8): 17121717. DOI: 10.1093/annonc/mdq013. ［13］ Hodi FS, Hoos A, Ibrahim R, et al. Novel efficacy criteria for antitumor activity to immunotherapt using the example of ipilimumab, and antiCTLA-4 monoclonal antibody［J］. J Clin Oncol, 2008, 26 Suppl: S19. ［14］ Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immunerelated response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab［J］. J Clin Oncol, 2016, 34(13):1510-1517. DOI: 10.1200/JCO.2015.64.0391. ［15］ Hoos A, Wolchok JD, Humphrey RW, et al. CCR 20th anniversary commentary: immunerelated response criteriacapturing clinical activity in immunooncology［J］. Clin Cancer Res, 2015, 21(22): 4989-4991. DOI: 10.1158/10780432.CCR143128. ［16］ Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage IIIB/IV nonsmallcell lung cancer: results from a randomized, doubleblind, multicenter phase Ⅱ study［J］. J Clin Oncol, 2012, 30(17): 2046-2054. DOI: 10.1200/JCO.2011.38.4032. ［17］ Nishino M, GiobbieHurder A, Gargano M, et al. Developing a common language for tumor response to immunotherapy: immunerelated response criteria using unidimensional measurements［J］. Clin Cancer Res, 2013, 19(14): 3936-3943. DOI: 10.1158/1078-0432.CCR-13-0895. ［18］ Nishino M, Gargano M, Suda M, et al. Optimizing immunerelated tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?［J］. J Immunother Cancer, 2014, 2: 17. DOI: 10.1186/2051-1426-2-17. ［19］ Bohnsack O, Ludajic K. Adaptation of the immunerelated response criteria: irRECIST［C］. ESMO, 2014: abstract 4958. ［20］ Rosenberg JE, HoffmanCensits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinumbased chemotherapy: a singlearm, multicentre, phase 2 trial［J］. Lancet, 2016, 387(10031): 1909-1920. DOI: 10.1016/S01406736(16)00561-4. ［21］ Tuomela M, Stanescu I, Krohn K. Validation overview of bioanalytical methods［J］. Gene Ther, 2005, 12 Suppl 1: S131S138. DOI: 10.1038/sj.gt.3302627. ［22］ Britten CM, Janetzki S, van der Burg SH, et al. Toward the harmonization of immune monitoring in clinical trials: quo vadis［J］. Cancer Immunol Immunother, 2008, 57(3): 285-288.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.